ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Harvard tests distinguish CFS from depressed & healthy subjects
Monday 4 July 2011
By Frank H Duffy, Anthony L Komaroff, et al.
[Note: the full text of this groundbreaking article is available here:http://www.biomedcentral.com/content/pdf/1471-2377-11-82.pdf. This report suggests that distinctive brain activity data may be used to help diagnose and/or differentiate CFS from depression, but further study is needed.]
The study’s objective was to determine if spectral coherence, a computational derivative of spectral analysis of the electroencephalogram (EEG), could distinguish patients with CFS from healthy control subjects and not erroneously classify depressed patients as having CFS.
Methods: This is a study, conducted in an academic medical center electroencephalography laboratory, of 632 subjects: 390 healthy normal controls, 70 patients with carefully defined CFS, 24 with major depression, and 148 with general fatigue.
Aside from fatigue, all patients were medically healthy by history and examination. EEGs were obtained and spectral coherences calculated after extensive artifact removal. Principal Components Analysis identified coherence factors and corresponding factor loading patterns.
Discriminant analysis determined whether spectral coherence factors could reliably discriminate CFS patients from healthy control subjects without misclassifying depression as CFS.
Results: Analysis of EEG coherence data from a large sample (n=632) of patients and healthy controls identified 40 factors explaining 55.6% total variance. Factors showed highly significant group differentiation (p<.0004) identifying:
• 89.5% of unmedicated female CFS patients
• And 92.4% of healthy female controls.
Recursive jackknifing showed predictions were stable.
A conservative 10-factor discriminant function model was subsequently applied, and also showed highly significant group discrimination (p<.001), accurately classifying;
• 88.9% unmedicated males with CFS,
• And 82.4% unmedicated male healthy controls.
No patient with depression was classified as having CFS.
The model was less accurate (73.9%) in identifying CFS patients taking psychoactive medications.
Factors involving the temporal lobes were of primary importance.
Conclusions: EEG spectral coherence analysis identified unmedicated patients with CFS and healthy control subjects without misclassifying depressed patients as CFS, providing evidence that CFS patients demonstrate brain physiology that is not observed in healthy normals or patients with major depression.
Studies of new CFS patients and comparison groups are required to determine the possible clinical utility of this test.
The results concur with other studies finding neurological abnormalities in CFS, and implicate temporal lobe involvement in CFS pathophysiology.
Source: BMC (BioMed Central) Neurology, July 1, 2011. doi:10.1186/1471-2377-11-82, by Duffy FH, McAnulty GB, McCreary MC, Cuchural GJ, Komaroff AJ. Departments of Neurology, Psychiatry, Children’s Hospital Boston & Harvard Medical School; Department of Medicine, Brigham & Women’s Hospital & Harvard Medical School; Department of medicine, Tufts Medical Center, Boston, Massachusetts. [Email: Anthony_komaroff@hms.harvard.edu]
The above originally appeared here.
blog comments powered by Disqus